Invasive fungal infections cause excessive morbidity and mortality in premature neonates and severely ill infants.
Safety and efficacy outcomes of micafungin were compared between prematurely and non-prematurely born infants <2 years of age. Data were obtained from all completed phase I–III clinical trials with micafungin that had enrolled infants (<2 years of age) that were listed in the Astellas Clinical Study Database. Demographics, adverse events, hepatic function tests and treatment success data were extracted and validated by the Astellas biostatistical group for all micafungin-treated patients, <2 years of age, using the unique patient identifier.
One-hundred and sixteen patients included in 9 clinical trials, 48% premature [birth weight (BW) <2500 g and/or gestational age <37 weeks], 52% non-premature, received ≥1 dose of micafungin. Among premature patients, 14.5% were low BW (1500–2499 g), 36.4% very low BW (1000–1499 g) and 49.1% extremely low BW (<1000 g). Ninety patients (78%) completed the studies; 13 [11% (4 premature)] died. Significantly more non-premature than premature patients discontinued treatment (P = 0.003). Treatment-related adverse events were recorded in 23% of patients with no difference between groups. More extremely low BW (n = 4, 15%) and very low BW (n = 8, 40%) infants experienced treatment-related adverse events than low BW (n = 0) and there was no relation to micafungin dose or duration. For a subgroup of 30 patients with invasive candidiasis, treatment success was achieved in 73% in both premature and non-premature groups. Prophylaxis was successful in 4/5 non-premature hematopoietic stem cell transplant patients.
Micafungin has a safe profile in premature and non-premature infants with substantial efficacy.
From the *Neonatology and NICU, S. Anna Hospital, Turin, Italy; †Astellas Pharma Global Development, Northbrook, IL; ‡Astellas Pharma Europe Ltd, Chertsey, United Kingdom; and §Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece.
Accepted for publication May 29, 2014.
This analysis and publication were funded by Astellas Pharma Europe Ltd. Paolo Manzoni has served as a scientific advisor and been a member on speaker bureaux for Astellas Pharma and Pfizer. Chunzhang Wu is an employee Astellas Pharma Global Development. Lorraine Tweddle is an employee Astellas Pharma Europe. Emmanuel Roilides has received research grants of significant value from Enzon, Gilead, Merck, Pfizer and Schering, has served as a scientific advisor for Astellas, Gilead, Merck, Pfizer, and Schering and been a member on speaker bureaux for Astellas, Aventis, Cephalon, Gilead, GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Schering and Wyeth.
The authors have no other funding or conflicts of interest to disclose.
Address for correspondence: Paolo Manzoni, MD, Neonatology and NICU, S. Anna Hospital, Azienda Ospedaliera Regina Margherita—S. Anna, C. Spezia 60, 10126 Turin, Italy. E-mail: firstname.lastname@example.org.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.